BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, entered into a ...
One stock that might be an intriguing choice for investors right now is Albireo Pharma, Inc. ALBO. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat ...
Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) is acquiring Albireo (NASDAQ:ALBO) in deal worth about $952M plus one contingent value right (CVR) per share to bolster its rare disease portfolio with treatments for ...
Ipsen’s near-$1 billion deal for Albireo was among a trio of biopharma acquisitions that opened this year’s J.P. Morgan Healthcare Conference. But Ipsen only got a chance to bid thanks to a sudden ...
BOSTON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the ...
What’s the best way to optimize the buzz for your new acquisition? Announce it at the kickoff of the annual J.P. Morgan Healthcare Conference. That’s the strategy Ipsen took on Monday, unveiling its ...
The regulator on Tuesday approved odevixibat, an Albireo Pharma drug developed to treat severe itching, or pruritus, in patients who have the liver disorder progressive familial intrahepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results